Histogen to Present at the HC Wainwright 22nd Annual Global Investment Conference
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the HC Wainwright 22nd Annual Global Investment Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the HC Wainwright 22nd Annual Global Investment Conference. Richard W. Pascoe, the company's President and CEO, will present on September 15, 2020, at 11:30 a.m. Eastern Time. The presentation will be available via a live webcast, with a replay accessible for 90 days following the event on Histogen's Investors page. Histogen focuses on restorative therapeutics that promote natural biological repair, utilizing innovative technologies for various therapeutic applications.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was +0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the HC Wainwright 22nd Annual Global Investment Conference. The virtual presentation is scheduled for Tuesday, September 15, 2020 at 11:30 a.m. Eastern Time.
Presentation Details
Date: Tuesday September 15, 2020
Time: 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time)
Live Webcast Link: https://wsw.com/webcast/hcw7/hsto/1625710
For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.histogen.com.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.